found that NEI-like DNA glycosylase III (NEIL3) activation of MEK/ERK signaling mediated epithelial–mesenchymal transition (EMT), that treatment resistance promoted HCC progression, and that NEIL3 induction of targeted inhibition of NEIL3 was a promising therapeutic approach in patients with HCC (111). The gene discussed is NEIL3; the disease is hepatocellular carcinoma.